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ratio = £60,197), MICA dominates L-AMB. The results of the
MC simulation and the sensitivity analyses showed that MICA
remained the most cost-effective option. CONCLUSION: The
lower costs and higher effectiveness reported for MICA versus
L-AMB in this analysis indicate MICA is the more cost-effective
therapy in the treatment of SCIs in the UK when compared to
L-AMB.
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OBJECTIVE: To estimate the cost-effectiveness of a national
immunization program against seasonal inﬂuenza targeting chil-
dren aged one to ﬁve years and adults aged 65+ years.
METHODS: Dynamic models simulate the indirect effect of vac-
cination conferred by herd protection, therefore, in order to
estimate the population effect of vaccination against inﬂuenza, a
transmission model comprising annual age classes was developed
to model the effects of age-speciﬁc infection, morbidity, and
mortality due to seasonal inﬂuenza. The structure of the
model followed the susceptible-latent-infected/morbid-recovered
schema for each age class. Transition between age classes was
modelled by either jumps to the next age class between inﬂuenza
seasons, or at a continuous rate. Assumptions concerning anti-
genic drift of the inﬂuenza strain were incorporated in the model
as the waning of vaccine-acquired immunity between successive
inﬂuenza seasons. Health beneﬁts were estimated using person-
years with inﬂuenza. Further developments are intended to
extend the outcome measures to include Quality-Adjusted Life
Years. Cost analysis was from a societal perspective in the
UK, however extension to other settings can be performed.
RESULTS: Assuming 60% vaccination coverage of the target
population in an inﬂuenza season, the ratio of person-years with
inﬂuenza to the initial population size is 0.99% for no vaccina-
tion and 0.85% with vaccination. This indicates that in the UK,
vaccination could prevent approximately 84,000 person-years of
inﬂuenza, which corresponds to 2,184,000 inﬂuenza episodes per
season, assuming infection lasts 2 weeks. The incremental cost
per person-year with inﬂuenza, with vaccination versus no vac-
cination was149. CONCLUSION: Initial results indicated that
the national immunization program targeting children aged 1–5
years and 65+ adults could be highly cost effective.
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OBJECTIVE: To estimate the CER of three health care delivery
models (HCDM) for HIV+ patients in Colombia. METHODS: A
review of 356 medical records from patients afﬁliated to institu-
tions under the Contributive Regimen in the Colombian Health
System was performed. The review incorporates data from 2002
to 2005, including disease status, treatment efﬁcacy, and costs of
care. VL and CD4 count data from the three-year analysis were
used as clinical outcomes. Direct costs included medications,
hospital expenses, doctor visits, laboratory tests, and other health
care providers costs. Description of the three models and analyses
of the services provided, teammembers, negotiations by planwere
described for each model. RESULTS: After controlling by disease
status and services utilization increase of CD4 count over the time
of the study was signiﬁcantly lower for patients in Model 3
(mean + 238 cells/mm3) than Model 1 (mean + 649 cells/mm3)
and Model 2 (mean + 676 cells/mm3). When VL was analyzed
patients in Model 1 had a higher decrease in VL levels -118,290
RNA copies vs. Model 2: -33,693 RNA copies and Model
3 = -33,504 RNA copies. Cost related to hospitalizations were
comparable in the threemodels and high differences were found in
the utilization and cost of outpatient services. However the overall
cost including antiretrovirals for patients in Model 1 was
$10,399.00, $11,617 forModel 2 and $11,002 forModel 3. After
a sensitivity analyses was performed CER were calculated. The
lower CER was $16.7 per CD4 cell/mm3 increased and $0.20 per
RNA copies decreased inModel 2 compared to $19 and $0.30 for
Model 1 and $26 and $0.58 for Model 3. CONCLUSIONS: Due
to differences in the plan characteristics and services utilization of
the Health Care Delivery Models, Model 2 appears to be a highly
cost-effective program relative to Model 1 and 3 health care
programs for HIV patients in Colombia.
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OBJECTIVE: Cytomegalovirus (CMV) remains the leading
opportunistic infection in the transplant population and is
responsible for numerous direct and indirect consequences. Some
clinical trials (Paya CV, et al. 2004; Ciancio G. et al. 2004) have
shown that prophylaxis with oral valganciclovir (VAL) is safe,
effective and less costly when compared with IV ganciclovir
(GAN) for the prevention of CMV infection in solid organ trans-
plant (SOT) recipients. Our aim was to compare costs and
medical resources of CMV infection prophylaxis in SOT recipi-
ents with oral VAL versus IV GAN in Brazil. METHODS: Based
on study of Paya CV, et al. 2004, we assumed the same efﬁcacy
for both oral VAL and IV GAN for the prevention of CMV
infection in SOT recipients. Therefore, a cost-minimization
analysis was developed to assess costs related to the prophylaxis
of CMV with oral VAL (900 mg/day) versus IV GAN (5 mg/kg/
day), under the payer’s perspective in Brazil. Only direct medical
costs (drugs, administration, physician fees and daily inpatient
care) were considered in this study. A panel with specialists was
conducted to reﬂect local practices. A 90-day timeframe was
considered based on the prophylaxis period which begins until
10 days after the transplant is done; consequently a discount rate
was not necessary. One-way sensitivity analyses were performed
to assess the robustness of the outcomes. RESULTS: Total costs
were R$17,673 for VAL and R$45,625, a savings of 61% per
patient. Cost-savings observed for VAL were due to lower costs
related to inpatient care (VAL: R$0 vs. GAN: R$29,520) and
lower administration costs (VAL: R$0 vs. GAN: R$7564). One-
way sensitivity analysis supported the robustness of the ﬁndings.
CONCLUSION: Findings suggest oral valganciclovir as a cost-
saving alternative for the prophylaxis of CMV infection in SOT
recipients under the payer perspective in Brazil.
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